Recently, PEGylated interleukin-2 (Bempegaldesleukin) has been shown to provide superior anti-tumor activity over native IL-2 and systemically expands anti-tumor CD8+ T cells while inducing Treg depletion in tumor tissue [61]. This evidence concerns the gene CD8A and neoplasm.